The Relevance of Biologically Effective Dose for Hearing Preservation After Stereotactic Radiosurgery for Vestibular Schwannomas: A Retrospective Longitudinal Study

Neurosurgery. 2023 Jun 1;92(6):1216-1226. doi: 10.1227/neu.0000000000002352. Epub 2023 Jan 24.

Abstract

Background: Stereotactic radiosurgery has become a common treatment approach for small-to-medium size vestibular schwannomas.

Objective: To evaluate relationship between time (beam-on and treatment) and risk of hearing decline after stereotactic radiosurgery for vestibular schwannomas in patients with Gardner-Robertson (GR) baseline classes I and II.

Methods: This retrospective longitudinal single-center study included 213 patients with GR I and II treated between June 2010 and December 2019. Risk of passing from GR classes I and II (coded 0) to other classes III, IV, and V (coded 1) and the increase in pure tone average (continuous outcome) were evaluated using a mixed-effect regression model. Biologically effective dose (BED) was further assessed for an alpha/beta ratio of 2.47 (Gy 2.47 ).

Results: Binary outcome analysis revealed sex, dose rate, integral dose, time [beam-on time odds ratio 1.03, P = .03, 95% CI 1.00-1.06; treatment time ( P = .02) and BED ( P = .001) as relevant. Fitted multivariable model included the sex, dose rate, and BED. Pure tone average analysis revealed age, integral dose received by tumor, isocenter number, time (beam-on time odds ratio 0.20, P = .001, 95% CI 0.083-0.33) and BED ( P = .005) as relevant.

Conclusion: Our analysis showed that risk of hearing decline was associated with male sex, higher radiation dose rate (cutoff 2.5 Gy/minute), higher integral dose received by the tumor, higher beam-on time ≥20 minutes, and lower BED. A BED between 55 and 61 was considered as optimal for hearing preservation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Follow-Up Studies
  • Hearing
  • Hearing Loss* / etiology
  • Hearing Loss* / prevention & control
  • Hearing Loss* / surgery
  • Humans
  • Longitudinal Studies
  • Male
  • Neuroma, Acoustic* / radiotherapy
  • Neuroma, Acoustic* / surgery
  • Radiosurgery* / adverse effects
  • Retrospective Studies
  • Treatment Outcome